Article
Alameda, CA-InSite Vision Inc.'s antibiotic product ISV-401 has proved safe and effective for treating acute bacterial conjunctivitis in a phase II clinical study.
Making the grade: FDA approves first biosimilar product for retinal diseases
Advancement in TED treatment is a bright spot
Comparable conscious sedation methods address individual patient needs
Investigators uncover health care disparities among US patients
Investigators zoom in on future of dry eye treatment
Analyzing opioid prescription patterns of US retina specialists